home / stock / bnox / bnox quote
Last: | $0.92005 |
---|---|
Change Percent: | 0.55% |
Open: | $0.925 |
Close: | $0.92005 |
High: | $0.948999 |
Low: | $0.8978 |
Volume: | 38,872 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.92005 | $0.925 | $0.92005 | $0.948999 | $0.8978 | 38,872 | 05-15-2024 |
$0.9301 | $0.915 | $0.9301 | $0.9688 | $0.9036 | 80,648 | 05-14-2024 |
$0.9219 | $0.93 | $0.9219 | $0.9682 | $0.91 | 30,029 | 05-13-2024 |
$0.9511 | $0.9455 | $0.9511 | $0.978 | $0.9352 | 13,910 | 05-10-2024 |
$0.9634 | $1 | $0.9634 | $1 | $0.9305 | 17,952 | 05-09-2024 |
$0.9613 | $0.96095 | $0.9613 | $0.9613 | $0.9364 | 16,733 | 05-08-2024 |
$0.96 | $0.995 | $0.96 | $1.0001 | $0.96 | 27,517 | 05-07-2024 |
$0.9878 | $0.97 | $0.9878 | $1.015 | $0.9558 | 33,183 | 05-06-2024 |
$0.96 | $0.95 | $0.96 | $0.97 | $0.93 | 23,511 | 05-03-2024 |
$0.9295 | $0.93 | $0.9295 | $0.94 | $0.9171 | 12,425 | 05-02-2024 |
$0.9108 | $0.9495 | $0.9108 | $0.979999 | $0.84 | 61,154 | 05-01-2024 |
$0.95 | $0.99 | $0.95 | $1.02 | $0.937 | 64,040 | 04-30-2024 |
$1.01 | $1.04 | $1.01 | $1.04 | $0.98 | 25,919 | 04-29-2024 |
$1 | $0.99 | $1 | $1 | $0.9336 | 45,062 | 04-26-2024 |
$0.9663 | $0.94 | $0.9663 | $1 | $0.9175 | 73,577 | 04-25-2024 |
$0.9469 | $0.9201 | $0.9469 | $0.953699 | $0.91 | 25,115 | 04-24-2024 |
$0.9232 | $0.95 | $0.9232 | $0.969501 | $0.9201 | 43,017 | 04-23-2024 |
$0.9599 | $0.9687 | $0.9599 | $0.9698 | $0.95 | 24,636 | 04-22-2024 |
$0.9794 | $0.99 | $0.9794 | $0.99 | $0.96 | 14,415 | 04-19-2024 |
$0.979999 | $0.97 | $0.979999 | $0.999 | $0.9591 | 18,036 | 04-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
Bionomics Limited Company Name:
BNOX Stock Symbol:
NASDAQ Market:
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post...
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continu...